Materia Medica Holding
Clinical trials sponsored by Materia Medica Holding, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Hope for women with chronic cystitis: raphamin trial aims to stop recurring UTIs Results expected Dec 2026 (estimated)
-
New drug raphamin aims to shorten bronchitis suffering
Symptom relief Recruiting nowThis Phase 3 trial tests whether the drug Raphamin can help adults with acute bronchitis recover faster. About 308 participants will take either Raphamin or a placebo for 5 days. Researchers will track symptoms like cough and chest pain to see if Raphamin reduces illness duration…
Phase 3 • Sponsor: Materia Medica Holding • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New drug raphamin aims to speed relief from sinus infection symptoms
Symptom relief Recruiting nowThis Phase 3 trial tests whether the drug Raphamin can quickly improve symptoms of acute rhinosinusitis (sinus infection) in adults. About 552 participants will receive either Raphamin or a placebo for a few days. The main goal is to see if more people feel much better by day 4 o…
Phase 3 • Sponsor: Materia Medica Holding • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
New pill aims to shorten Kids' colds – trial underway
Symptom relief Recruiting nowThis phase 3 trial tests whether Raphamin tablets can reduce cold symptoms in 374 children aged 3 to 12. Children with fever and other cold signs will receive either Raphamin or a placebo. The main goal is to see how quickly symptoms like fever and congestion go away.
Phase 3 • Sponsor: Materia Medica Holding • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
New cough syrup for toddlers under trial this flu season
Symptom relief Recruiting nowThis study tests whether a liquid medicine called Rengalin can safely reduce coughing in children aged 6 months to 3 years who have a viral cold or flu. About 264 children will take either Rengalin or a placebo three times a day for 7 days. The main goal is to see if more childre…
Phase 3 • Sponsor: Materia Medica Holding • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC